Leone D Patterson
CIK 1233539 · View on SEC EDGAR ↗
Insider
First SEC filing: June 4, 2026 · Latest: June 4, 2026
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net:
$0
+ 21 non-open-market transactions below
last 12 months, based on the transactions shown below
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
21 other filings hidden
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 16, 2024 | TNYA | S | 5,201 | $5.86 | $30,478 | 60,755 Direct | -7.89% | Disposed | -87.7% (price as of 2026-08-19) |
| Aug. 16, 2023 | TNYA | S | 4,452 | $3.81 | $16,962 | 64,542 Direct | -6.45% | Disposed | -81.1% (price as of 2026-08-19) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 10, 2026 | NKTX | Stock Option (right to buy) | Common Stock (37,000) | $2.46 | June 9, 2036 | 37,000 | Acquired |
| June 3, 2026 | KLRS | Stock Option (Right to Buy) | Common Stock (9,000) | $4.72 | June 2, 2036 | 9,000 | Acquired |
| June 5, 2025 | NKTX | Stock Option (right to buy) | Common Stock (46,000) | $1.83 | June 4, 2035 | 46,000 | Acquired |
| April 10, 2025 | KLRS | Stock Option (Right to Buy) | Common Stock (18,000) | $7.31 | April 9, 2035 | 18,000 | Acquired |
| Jan. 10, 2025 | ZYME | Restricted Stock Unit | Common Stock (53,000) | — | — | 53,000 | Acquired |
| Jan. 10, 2025 | ZYME | Stock Option (Right to Buy) | Common Stock (79,000) | $13.22 | Jan. 9, 2035 | 79,000 | Acquired |
| Sept. 1, 2024 | ZYME | Stock Option (Right to Buy) | Common Stock (360,000) | $11.73 | Aug. 31, 2034 | 360,000 | Acquired |
| June 13, 2024 | NKTX | Stock Option (right to buy) | Common Stock (22,500) | $6.23 | June 12, 2034 | 22,500 | Acquired |
| Feb. 23, 2024 | TNYA | Stock Option (Right to buy) | Common Stock (205,000) | $5.22 | Feb. 22, 2034 | 205,000 | Acquired |
| June 7, 2023 | NKTX | Stock Option (right to buy) | Common Stock (22,500) | $4.86 | June 6, 2033 | 22,500 | Acquired |
| Feb. 15, 2023 | TNYA | Stock Option (Right to buy) | Common Stock (190,000) | $3.06 | Feb. 14, 2033 | 190,000 | Acquired |
| June 8, 2022 | NKTX | Stock Option (right to buy) | Common Stock (16,000) | $14.95 | June 7, 2032 | 16,000 | Acquired |
| May 19, 2022 | CLYM | Stock Option (Right To Buy) | Common Stock (10,000) | $3.46 | May 18, 2032 | 10,000 | Acquired |
| Feb. 15, 2022 | TNYA | Stock Option (Right to buy) | Common Stock (66,000) | $15.19 | Feb. 14, 2032 | 66,000 | Acquired |
| June 13, 2021 | NKTX | Stock Option (right to buy) | Common Stock (16,511) | $25.03 | June 12, 2031 | 16,511 | Acquired |
| July 9, 2020 | NKTX | Stock Option (right to buy) | Common Stock (18,300) | $18.00 | July 8, 2030 | 18,300 | Acquired |
| July 9, 2020 | NKTX | Stock Option (right to buy) | Common Stock (10,700) | $18.00 | July 8, 2030 | 10,700 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 6 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Sept. 3, 2024 | ZYME | No securities are beneficially owned | 0 | Direct |
| Sept. 3, 2024 | ZYME | No securities are beneficially owned→ Not applicable (0) | 0 | Direct |
| Aug. 9, 2021 | CLYM | Stock Option (Right to Buy)→ Common Stock (39,198) | 39,198 | Direct |
| Aug. 9, 2021 | CLYM | Stock Option (Right to Buy)→ Common Stock (15,383) | 15,383 | Direct |
| July 29, 2021 | TNYA | Stock Option (Right to Buy)→ Common Stock (354,166) | 354,166 | Direct |
| July 9, 2020 | NKTX | Stock Option (right to buy)→ Common Stock | — | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $349,528 | — | — | — | — | — | $1,424 | $1,364,989 |
| 2023 | $455,000 | — | — | — | $160,000 | — | $4,384 | $1,273,581 |
| 2022 | $445,609 | — | — | — | $133,500 | — | $4,930 | $1,365,241 |
ZYME
Exec. VP, Chief Business Officer & CFO(7)| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2024 | $161,667 | $50,000 | — | — | $99,849 | — | $6,063 | $2,907,982 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.